Friday, January 21, 2022
HomeLatest NewsFederal NewsFDA issued draft guidance aimed at boosting generic drug competition

FDA issued draft guidance aimed at boosting generic drug competition

PoliticoPRO: By Sarah Owermohle

​The FDA released draft guidance today aimed at boosting generic drug competition by clarifying manufacturers must disclose whether approved products are on the market.

The guidance calls for updating approved generics’ marketing status in the FDA’s “Orange Book,” a database of generic drug details, so potential manufacturers can see how many versions of one product are on the market. Currently, the database doesn’t distinguish whether an approved generic was never launched or has been discontinued, but Congress cleared FDA to impose the new requirements in the agency’s last reauthorization in 2017.

Commissioner Scott Gottlieb said the move would help FDA understand why generic companies never marketed a product after receiving agency approval.Today’s guidance is the first of several steps the agency is planning this year to encourage generic competition.

FDA is also asking for comments on how to improve the Orange Book, including whether outside patents — such as those for digital applications tied to the approved medicine — should also be included in the database so would-be manufacturers have a better idea of potential hurdles.

“The FDA must work to make generic drug development more efficient and predictable,” Gottlieb said.​

Stay Connected

Unified Voice Newsletter

Events This Month


25jan12:00 pm1:00 pmEffectively Using the QAPI Process to Implement a Wound ProgramSDAHO Webinar12:00 pm - 1:00 pm CST Event Type :Education Events,Webinar

27jan12:00 pm1:00 pmSD Dimensions: Reports and DashboardsSDAHO Webinar12:00 pm - 1:00 pm CST Event Type :Education Events,Webinar

28jan9:00 am12:00 pmSDSU Nursing Career Fair9:00 am - 12:00 pm CST


By submitting this form, you are consenting to receive marketing emails from: SDAHO, 3708 W Brooks Place, Sioux Falls, SD, 57106, You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact